Trials / Recruiting
RecruitingNCT07400471
The Effects of Preemptive Multimodal Analgesic on Endodontic Pain Following Root Canal Therapy.
The Effects of Preemptive Multimodal Analgesic on Endodontic Pain.
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 280 (estimated)
- Sponsor
- Chattogram International Dental College · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A clinical trial comparing preemptive multimodal analgesics with placebo in the management of immediate and chronic post-endodontic pain. The study utilizes statistical methods such as chi-squared, T-tests, and regression analysis, accounting for multiple outcomes with the Bonferroni adjustment. Duloxetine hydrochloride and pregabalin, both available in Bangladesh, are evaluated as experimental drugs, while placebos are used to assess psychological effects on pain. All participants receive standard interventional treatments, with acetaminophen provided as needed, and ethical considerations are addressed according to international guidelines.
Conditions
- Post Endodontic Pain
- Mechanical Detection Threshold
- Mechanical Pain Threshold
- Mechanical Pain Sensitivity
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin- Acetaminophen | Preemptive Multi modal analgesic drug: Experimental group will be divided into 2 subgroups according to use of drug. A. Pregabalin-acetaminophen. B. Duloxetine-Acetaminophen Pregabalin-acetaminophen: Before a half-hour endodontic treatment, patients in this group will receive a single dosage of 50 mg pregabalin and 500 mg acetaminophen. If necessary, acetaminophen dosages of 500 mg will be administered three times a day. |
| DRUG | Duloxetine- Acetaminophen | Duloxetine-Acetaminophen: Prior to a half-hour endodontic treatment, patients in this group will receive a single dosage of 500 mg of acetaminophen and 30 mg of Duloxetine. If necessary, acetaminophen dosages of 500 mg will be administered three times a day. |
Timeline
- Start date
- 2026-02-06
- Primary completion
- 2027-03-30
- Completion
- 2027-04-30
- First posted
- 2026-02-10
- Last updated
- 2026-02-11
Locations
1 site across 1 country: Bangladesh
Source: ClinicalTrials.gov record NCT07400471. Inclusion in this directory is not an endorsement.